According to Zhitong Finance App, Luzhu Bio-B (02480) announced that the recombinant respiratory syncytial virus (RSV) vaccine (recombinant RSV vaccine) developed by the Group has been approved by the National Drug Administration of the People's Republic of China (China), and clinical trials can be carried out in China.

This product is a candidate for a recombinant protein vaccine developed independently by the Group to prevent lower respiratory disease (LRTD) caused by RSV. It is a liquid aluminum-containing adjuvant vaccine that uses RSV fused with pre-F (Pre-F) protein antigen. The approval of this clinical trial lays a solid foundation for the Group's subsequent recombinant protein vaccine candidate development work.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.